Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14254658 | 1.00 | CYP2B6 (0.65) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| SCHEMBL2961712 | 1.00 | CYP2B6 (0.65) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| Hydrochloric Acid SCHEMBL27926211 | 0.98 | CYP2B6 (0.63) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| SCHEMBL14254668 | 0.90 | CYP2B6 (0.59) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| SCHEMBL14254664 | 0.90 | CYP2B6 (0.59) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| SCHEMBL7664060 | 0.90 | CYP2B6 (0.59) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| Hydrochloric Acid SCHEMBL17048494 | 0.89 | CYP2B6 (0.57) | CYP2B6CYP19A1HRH3HRH4TBXAS1 | |
| SCHEMBL13736636 | 0.83 | CYP2B6 (0.61) | CYP2B6CYP19A1TBXAS1 | |
| SCHEMBL11051252 | 0.81 | CYP2B6 (0.89) | CYP2B6CYP19A1TBXAS1 | |
| SCHEMBL11047050 | 0.81 | CYP2B6 (0.96) | CYP2B6CYP19A1HRH3HRH4TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | claimed |
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | disclosed |
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | ONCOTARTIS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20190031658-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | ONCOTARTIS INC. | 2019-01-31 | — | — | US | disclosed |
| EP-2655357-B1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO SA (CH) | 2016-06-22 | — | — | EP | disclosed |
| US-9073892-B2 | Indazolyl triazol derivatives | MERCK SERONO S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1632483-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1362039-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | AVENTIS PHARMACEUTICAL INC. (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | NAMPT, NNT, NADK | CYP2B6 767/4885CYP19A1 2463/4885HRH3 404/4885 |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | DRD3, DRD2, DRD1 | CYP2B6 1722/4885CYP19A1 3360/4885HRH3 80/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | CYP2B6 1915/4885CYP19A1 512/4885HRH3 533/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | CYP2B6 1467/4885CYP19A1 3129/4885HRH3 59/4885 |
| US-20190031658-A1 | BENZAMIDE AND NICOTINAMIDE COMPOUNDS AND METHODS OF USING SAME | NNT, NAMPT, NNMT | CYP2B6 1427/4885CYP19A1 1768/4885HRH3 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.